Day: December 19, 2024

Aspocomp Group Plc, Stock Exchange Release, December 19, 2024 at 8:00 a.m. (Finnish time) The Shareholders’ Nomination Board of Aspocomp Group Plc submits the following proposals to the Annual General Meeting, planned to be held on April 29, 2025. The proposals will also be included in the Notice to the Annual General Meeting 2025 to be published at the later date. Number of Board members The Shareholder’s Nomination Board proposes to the Annual General Meeting that four members be elected to the Board of Directors. Members of the Board of Directors The Shareholder’s Nomination Board proposes to the Annual General Meeting that the current members of the Board of Directors Mr. Anssi Korhonen and Mr. Ville Vuori be re-elected as members to the Board of Directors and Ms. Jenni Enroth and Ms. Kaisa Kokkonen be elected as new members of...

Communiqué de presse Convening of the Annual General Meeting to approve the 2023 financial statements to be held on January 31, 2025 and evolution of the Atos Board of Directors Paris, France, December 19, 2024 Convening of Annual General Meeting The meeting notice (avis de réunion) for the General Meeting scheduled for January 31, 2025, containing the agenda, the draft resolutions, and the participation and voting procedures for this Meeting, will be published in the Official Legal Gazette (Bulletin des Annonces Légales Obligatoires BALO) on December 25, 2024, and will be available on the Company’s website (https://atos.net/en/investors/annual-general-meeting). Evolution of the composition of Atos Board of Directors Atos’ Board of Directors, upon the recommendation of the Nominations and Governance Committee, chaired by Elizabeth Tinkham,...

Driving Breakthroughs in 3D Naked-Eye and AR/VR Technologies with High Performance, Low Latency, and Versatile Applications TAINAN, Taiwan, Dec. 19, 2024 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (“Himax” or “Company”) (Nasdaq: HIMX), an industry leader in fabless display driver ICs and other semiconductors, today announced the Company will showcase its industry-leading, low-latency 3D naked-eye display solution at CES 2025, featuring Himax’s exclusive “3D Display Pixel Weaving” and patented “Structured Light 3D Visual AI” technologies. Leveraging years of 3D development expertise, Himax’s 3D naked-eye display solution is an integrated and comprehensive offering that provides cutting-edge reference designs for a wide array of 3D AR/VR applications, accelerating customer product development to meet the rapidly growing AR/VR...

Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”) today announce that QUVIVIQ™ (daridorexant) 25 and 50 mg has been launched and is now available in Japan as a new treatment for adults with insomnia. QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep. Nxera Pharma Japan Co., Ltd. (a wholly owned subsidiary of Nxera Pharma) is the approval holder and will be responsible in part for provision of drug product. Shionogi will be solely responsible for distribution and sales...

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), a life-threatening condition with high mortality rates. In a single-arm, multi-center, Phase 3 trial of children with SR-aGvHD, 89% of whom had high severity Grade C or Grade D disease, 70% achieved an overall response by Day 28 of treatment with RYONCIL, a measure that predicts survival in aGVHD. RYONCIL’S immunomodulatory effects, including inhibition of T cell activation and secretion of pro-inflammatory cytokines, position the therapy for potential other indications in diseases with excessive inflammation.  NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) — Mesoblast...

RENO, NV, Dec. 18, 2024 (GLOBE NEWSWIRE) — Winvest Group Limited (OTCQB: WNLV) (“Winvest”), an investment holding company with diverse media, entertainment, and technology portfolios, is thrilled to announce that its stock – currently traded on the OTC Markets under the ticker WNLV – was upgraded from “Pink Sheets” status to OTCQB, as approved by the U.S. Securities and Exchange Commission (SEC), on December 9, 2024. Also known as “The Venture Market,” OTCQB is the middle tier of the over-the-counter market for U.S. stocks.“This massively important milestone reflects our commitment to growth, transparency, financial discipline, and shareholder value,” said Jeffrey Wong, CEO of Winvest. “In addition, the move to OTCQB offers tremendous benefits, including enhanced...